Quick View: FDA Approves BMS's Breyanzi, Making It The First CAR-T Cell Therapy Indicated For Two Types Of Leukaemia
Pharmaceuticals / United States / Mon 18 Mar, 2024
The Latest: On March 14 2024, Bristol Myers Squibb (BMS) secured an accelerated FDA approval for Breyanzi (lisocabtagene maraleucel) as the first and only CAR T-cell therapy for adults with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). The approval is based on positive results from a Phase I/II